<DOC>
	<DOCNO>NCT01166620</DOCNO>
	<brief_summary>To quantify incremental cost infection patient treat etanercept , adalimumab infliximab versus abatacept .</brief_summary>
	<brief_title>Observational Real-world Evaluation Cost Infections Rheumatoid Arthritis ( RA ) Patients Biologics</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>18 year age old ; Have diagnosis rheumatoid arthritis ( ICD9:714x.xx ) ; Have enrol least 6 month 6 month assessment 12 month 12 month assessment ; enrol health plan February 2006 June 2009 claim indicate least one use either abatacept , etanercept , adalimumab infliximab least 6 month teh 6 month assessment 12 month 12 month assessment Patients continuously eligible health plan benefit evaluation period exclude Patients biologics 6 12 month postindex period exclude ( ex . abatacept cohort exclude also claim etanercept 6 12 month postindex period ) . Patients biologics 6 month prior biologic index date also exclude Patients diagnosis nonRA condition commonly treat biologics ( ex . Crohn 's disease ) 6 month preindex period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>